Sample size calculation
CASTLE
The study will be powered to address the primary hypothesis that PV isolation will reduce the total AF burden compared to patients undergoing a sham procedure at 6 months post‐randomisation. The CASTLE AF trial reported AF burden using continuous monitoring at 3 months in the ablation group to be 27% and 51% in the pharmacological group. At 6 months the AF burden in the ablation group was reported to be 23% versus 51% in the pharmacological group.